ÂÜÀòÂÒÂ×

Mario Marcondes, MD PhD has extensive work experience in the field of clinical development and research. Mario has held various positions at different companies and institutions.

At Nektar Therapeutics, Mario started as a Medical Director in Clinical Development in March 2017. Mario then became a Senior Medical Director in October 2018 and later an Executive Director in December 2019, where they were responsible for leading the clinical development of innovative therapeutic compounds and conducting phase 1-2 clinical studies, primarily focusing on oncology and immunology. Currently, they serve as the Vice President and Head of Clinical Development.

Prior to joining Nektar Therapeutics, Mario worked at Gilead Sciences as an Associate Director of Clinical Research. Their responsibilities at Gilead included serving as the clinical lead on cross-functional development teams for investigational compounds in Oncology and Inflammation. Mario also played a crucial role in designing and executing Phase I/II clinical trials and providing medical and scientific direction in regulatory matters.

Before their industry experience, Mario held research positions at the University of Washington and the Fred Hutchinson Cancer Research Center. At the University of Washington, they worked as an Assistant Professor, focused on research proposal design and experimental execution. At the Fred Hutchinson Cancer Research Center, they served as a Research Member and a Post Doctoral Fellow, where they gained expertise in various laboratory techniques and provided patient support.

Overall, Mario Marcondes has a diverse background in clinical development, research, and academia, with a strong focus on oncology and immunology.

Dr. Mario Marcondes has an extensive education history in the medical field. Mario obtained their Bachelor of Medicine (MD) degree from Taubate Sao Paulo Medical School from 1994 to 2000, with a specialization in Biology, General. Following this, they completed two medical residency programs at Public Servant Hospital Sao Paulo SP. From 2000 to 2002, they focused on Internal Medicine, and from 2002 to 2004, they specialized in Hematology-Oncology.

Dr. Marcondes then pursued further education and received a PhD in Pathology/Experimental Pathology from the University of Washington from 2006 to 2010. Additionally, they participated in a Summer Elective in Internal Medicine at Harvard Medical School in 1998-1999.

In terms of certifications, Dr. Marcondes is a member of several reputable organizations. Mario obtained membership in the American Association for Cancer Research (AACR) in December 2017, the Society for Immunotherapy of Cancer (SITC) in November 2017, the American Society of Clinical Oncology (ASCO) in June 2016, the American Society of Hematology in February 2008, and the International Society of Experimental Hematology (ISEH) in January 2008.